Lincz Lisa F, Gupta Sanjiv A, Wratten Christopher R, Kilmurray Janice, Nash Sharon, Seldon Michael, O'Brien Peter C, Bell Katy J L, Denham James W
Department of Haematology, Calvary Mater Newcastle, NSW, Australia.
Radiother Oncol. 2009 Jan;90(1):136-40. doi: 10.1016/j.radonc.2008.10.002. Epub 2008 Nov 13.
Biological mechanisms underlying radiation induced erythema remain largely unknown, with no simple way to accurately predict or prevent extreme cases. Based on the recent findings in patients suffering from chronic urticaria, we sought to determine if similar mechanisms of hypercoagulation contributed to comparable skin reactions during radiotherapy.
Plasma levels of prothrombin factor 1+2 (F1+2), D-dimers and plasminogen activator inhibitor-1 (Pai-1) were tested in 32 women undergoing irradiation following breast conserving surgery for early breast cancer. Reflectance spectrophotometry was used to objectively assess erythema throughout the treatment by measuring the amount of light reflected from the skin surface as a function of wavelength. Correlations between peak levels of erythema and plasma biomarkers were then assessed.
Individual peak reflectance readings generally occurred between day 29 of treatment and 2 weeks post radiotherapy, and represented a median increase of 66% (range: 11-146%; p<0.001) from baseline. Peak reflectance correlated with F1+2 and Pai-1 levels measured both at baseline and day 29 of treatment, and multivariate analysis indicated that these two baseline measurements were the best predictors of peak reflectance, accounting for 59% of the variability in erythema (p=0.000004).
Patients with signs of intravascular thrombin generation are at higher risk of radiotherapy-induced skin reactions, providing a new therapeutic avenue for possibly predicting and preventing this side effect of cancer treatment.
辐射诱发红斑的生物学机制在很大程度上仍不清楚,尚无简单方法能准确预测或预防极端情况。基于近期对慢性荨麻疹患者的研究结果,我们试图确定放疗期间类似的高凝机制是否会导致类似的皮肤反应。
对32例因早期乳腺癌接受保乳手术后放疗的女性患者,检测其血浆凝血酶原因子1+2(F1+2)、D-二聚体和纤溶酶原激活物抑制剂-1(Pai-1)水平。采用反射分光光度法,通过测量皮肤表面反射光量随波长的变化,客观评估整个治疗过程中的红斑情况。然后评估红斑峰值水平与血浆生物标志物之间的相关性。
个体反射率峰值读数一般出现在治疗第29天至放疗后2周之间,较基线水平中位数增加66%(范围:11%-146%;p<0.001)。反射率峰值与基线及治疗第29天测得的F1+2和Pai-1水平相关,多变量分析表明这两个基线测量值是反射率峰值的最佳预测指标,可解释红斑变异性的59%(p=0.000004)。
有血管内凝血酶生成迹象的患者发生放疗诱发皮肤反应的风险更高,这为预测和预防癌症治疗的这一侧面效应提供了一条新的治疗途径。